Alnylam’s novel RNA therapy Onpattro wins nod for hATTR amyloidosis
The US Food and Drug Administration has approved Alnylam’s RNAi therapeutic Onpattro for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Read More
